TY - JOUR AU - Duncan, L. M. PY - 2009 DA - 2009// TI - The classification of cutaneous melanoma JO - Hematol Oncol Clin North Am VL - 23 UR - https://doi.org/10.1016/j.hoc.2009.03.013 DO - 10.1016/j.hoc.2009.03.013 ID - Duncan2009 ER - TY - JOUR AU - Ribas, A. AU - Hamid, O. AU - Daud, A. AU - Hodi, F. S. AU - Wolchok, J. D. AU - Kefford, R. PY - 2016 DA - 2016// TI - Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma JO - JAMA VL - 315 UR - https://doi.org/10.1001/jama.2016.4059 DO - 10.1001/jama.2016.4059 ID - Ribas2016 ER - TY - STD TI - Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med. 2014;372:320–30. https://doi.org/10.1056/NEJMoa1412082. ID - ref3 ER - TY - JOUR AU - Hodi, F. S. AU - Chiarion-Sileni, V. AU - Gonzalez, R. AU - Grob, J. -. J. AU - Rutkowski, P. AU - Cowey, C. L. PY - 2018 DA - 2018// TI - Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30700-9 DO - 10.1016/S1470-2045(18)30700-9 ID - Hodi2018 ER - TY - JOUR AU - Wolchok, J. D. AU - Chiarion-Sileni, V. AU - Gonzalez, R. AU - Rutkowski, P. AU - Grob, J. -. J. AU - Cowey, C. L. PY - 2017 DA - 2017// TI - Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1709684 DO - 10.1056/NEJMoa1709684 ID - Wolchok2017 ER - TY - JOUR AU - Balch, C. M. AU - Gershenwald, J. E. AU - Soong, S. J. AU - Thompson, J. F. AU - Atkins, M. B. AU - Byrd, D. R. PY - 2009 DA - 2009// TI - Final version of 2009 AJCC melanoma staging and classification JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/jco.2009.23.4799 DO - 10.1200/jco.2009.23.4799 ID - Balch2009 ER - TY - JOUR AU - Nosrati, A. AU - Tsai, K. K. AU - Goldinger, S. M. AU - Tumeh, P. AU - Grimes, B. AU - Loo, K. PY - 2017 DA - 2017// TI - Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy JO - Br J Cancer VL - 116 UR - https://doi.org/10.1038/bjc.2017.70 DO - 10.1038/bjc.2017.70 ID - Nosrati2017 ER - TY - JOUR AU - Heer, E. C. AU - Brouwers, A. H. AU - Boellaard, R. AU - Sluiter, W. J. AU - Diercks, G. F. H. AU - Hospers, G. A. P. PY - 2018 DA - 2018// TI - Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative (18) F-FDG PET/CT analysis JO - EJNMMI Res VL - 8 UR - https://doi.org/10.1186/s13550-018-0453-x DO - 10.1186/s13550-018-0453-x ID - Heer2018 ER - TY - JOUR AU - Weide, B. AU - Elsässer, M. AU - Büttner, P. AU - Pflugfelder, A. AU - Leiter, U. AU - Eigentler, T. K. PY - 2012 DA - 2012// TI - Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis JO - Br J Cancer VL - 107 UR - https://doi.org/10.1038/bjc.2012.306 DO - 10.1038/bjc.2012.306 ID - Weide2012 ER - TY - STD TI - von Schoultz E, Hansson LO, Djureen E, Hansson J, Kärnell R, Nilsson B, et al. Prognostic value of serum analyses of S-100β protein in malignant melanoma. Melanoma Res. 1996;6:133–8. https://doi.org/10.1097/00008390-199604000-00008. ID - ref10 ER - TY - STD TI - Mårtenson ED, Hansson LO, Nilsson B, Ev S, Brahme EM, Ringborg U, et al. Serum S-100B Protein as a Prognostic Marker in Malignant Cutaneous Melanoma.. J Clin Oncol. 2001;19:824–31. https://doi.org/10.1200/jco.2001.19.3.824. ID - ref11 ER - TY - STD TI - Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: A meta-analysis. Int J Cancer 2008;123:2370–6. https://doi.org/10.1002/ijc.23794. ID - ref12 ER - TY - JOUR AU - Egberts, F. AU - Kotthoff, E. M. AU - Gerdes, S. AU - Egberts, J. H. AU - Weichenthal, M. AU - Hauschild, A. PY - 2012 DA - 2012// TI - Comparative study of YKL-40, S-100B and LDH as monitoring tools for stage IV melanoma JO - Eur J Cancer VL - 48 UR - https://doi.org/10.1016/j.ejca.2011.08.007 DO - 10.1016/j.ejca.2011.08.007 ID - Egberts2012 ER - TY - STD TI - Fang S, Wang Y, Sui D, Liu H, Ross MI, Gershenwald JE, et al. C-Reactive Protein As a Marker of Melanoma Progression. J Clin Oncol 2015;33:1389–96. https://doi.org/10.1200/jco.2014.58.0209. ID - ref14 ER - TY - JOUR AU - Deichmann, M. AU - Kahle, B. AU - Moser, K. AU - Wacker, J. AU - Wüst, K. PY - 2004 DA - 2004// TI - Diagnosing melanoma patients entering American joint committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase JO - Br J Cancer VL - 91 UR - https://doi.org/10.1038/sj.bjc.6602043 DO - 10.1038/sj.bjc.6602043 ID - Deichmann2004 ER - TY - JOUR AU - Wang, Y. AU - Zhang, H. AU - Yang, Y. AU - Zhang, T. AU - Ma, X. PY - 2019 DA - 2019// TI - Prognostic Value of Peripheral Inflammatory Markers in Preoperative Mucosal Melanoma: A Multicenter Retrospective Study JO - Front Oncol VL - 9 UR - https://doi.org/10.3389/fonc.2019.00995 DO - 10.3389/fonc.2019.00995 ID - Wang2019 ER - TY - STD TI - Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic Performance of Whole Body Dual Modality 18F-FDG PET/CT Imaging for N- and M-Staging of Malignant Melanoma: Experience With 250 Consecutive Patients. J Clin Oncol 2006;24:1178–87. https://doi.org/10.1200/jco.2005.03.5634. ID - ref17 ER - TY - JOUR AU - Larson, S. M. AU - Erdi, Y. AU - Akhurst, T. AU - Mazumdar, M. AU - Macapinlac, H. A. AU - Finn, R. D. PY - 1999 DA - 1999// TI - Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in Total lesion glycolysis JO - Clin Positron Imaging VL - 2 UR - https://doi.org/10.1016/S1095-0397(99)00016-3 DO - 10.1016/S1095-0397(99)00016-3 ID - Larson1999 ER - TY - JOUR AU - Biehl, K. J. AU - Kong, F. M. AU - Dehdashti, F. AU - Jin, J. Y. AU - Mutic, S. AU - Naqa, I. PY - 2006 DA - 2006// TI - 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? JO - J Nucl Med VL - 47 ID - Biehl2006 ER - TY - JOUR AU - Lee, J. W. AU - Kang, C. M. AU - Choi, H. J. AU - Lee, W. J. AU - Song, S. Y. AU - Lee, J. H. PY - 2014 DA - 2014// TI - Prognostic value of metabolic tumor volume and Total lesion glycolysis on preoperative (1)(8) F-FDG PET/CT in patients with pancreatic Cancer JO - J Nucl Med VL - 55 UR - https://doi.org/10.2967/jnumed.113.131847 DO - 10.2967/jnumed.113.131847 ID - Lee2014 ER - TY - JOUR AU - Armstrong, I. S. AU - Kelly, M. D. AU - Williams, H. A. AU - Matthews, J. C. PY - 2014 DA - 2014// TI - Impact of point spread function modelling and time of flight on FDG uptake measurements in lung lesions using alternative filtering strategies JO - EJNMMI Physics VL - 1 UR - https://doi.org/10.1186/s40658-014-0099-3 DO - 10.1186/s40658-014-0099-3 ID - Armstrong2014 ER - TY - JOUR AU - Vanderhoek, M. AU - Perlman, S. B. AU - Jeraj, R. PY - 2012 DA - 2012// TI - Impact of the definition of peak standardized uptake value on quantification of treatment response JO - J Nuclear Med VL - 53 UR - https://doi.org/10.2967/jnumed.111.093443 DO - 10.2967/jnumed.111.093443 ID - Vanderhoek2012 ER - TY - JOUR AU - Lodge, M. A. AU - Chaudhry, M. A. AU - Wahl, R. L. PY - 2012 DA - 2012// TI - Noise considerations for PET quantification using maximum and peak standardized uptake value JO - J Nucl Med VL - 53 UR - https://doi.org/10.2967/jnumed.111.101733 DO - 10.2967/jnumed.111.101733 ID - Lodge2012 ER - TY - JOUR AU - Wahl, R. L. AU - Jacene, H. AU - Kasamon, Y. AU - Lodge, M. A. PY - 2009 DA - 2009// TI - From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors JO - J Nuclear Med VL - 50 UR - https://doi.org/10.2967/jnumed.108.057307 DO - 10.2967/jnumed.108.057307 ID - Wahl2009 ER - TY - JOUR AU - Sher, A. AU - Lacoeuille, F. AU - Fosse, P. AU - Vervueren, L. AU - Cahouet-Vannier, A. AU - Dabli, D. PY - 2016 DA - 2016// TI - For avid glucose tumors, the SUV peak is the most reliable parameter for [(18) F]FDG-PET/CT quantification, regardless of acquisition time JO - EJNMMI Res VL - 6 UR - https://doi.org/10.1186/s13550-016-0177-8 DO - 10.1186/s13550-016-0177-8 ID - Sher2016 ER - TY - JOUR AU - Ito, K. AU - Schöder, H. AU - Teng, R. AU - Humm, J. L. AU - Ni, A. AU - Wolchok, J. D. PY - 2019 DA - 2019// TI - Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy JO - Eur J Nucl Med Mol Imaging VL - 46 UR - https://doi.org/10.1007/s00259-018-4211-0 DO - 10.1007/s00259-018-4211-0 ID - Ito2019 ER - TY - STD TI - Son SH, Kang SM, Jeong SY, Lee S-W, Lee S-J, Lee J, et al. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma. Clin Nucl Med 2016;41:e266–e73. https://doi.org/10.1097/rlu.0000000000001205. ID - ref27 ER - TY - JOUR AU - Ribas, A. AU - Puzanov, I. AU - Dummer, R. AU - Schadendorf, D. AU - Hamid, O. AU - Robert, C. PY - 2015 DA - 2015// TI - Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial JO - Lancet Oncol. VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00083-2 DO - 10.1016/S1470-2045(15)00083-2 ID - Ribas2015 ER - TY - JOUR AU - Pfannenberg, C. AU - Gueckel, B. AU - Wang, L. AU - Gatidis, S. AU - Olthof, S. C. AU - Vach, W. PY - 2019 DA - 2019// TI - Practice-based evidence for the clinical benefit of PET/CT-results of the first oncologic PET/CT registry in Germany JO - Eur J Nucl Med Mol Imaging VL - 46 UR - https://doi.org/10.1007/s00259-018-4156-3 DO - 10.1007/s00259-018-4156-3 ID - Pfannenberg2019 ER - TY - JOUR AU - Forschner, A. AU - Olthof, S. C. AU - Guckel, B. AU - Martus, P. AU - Vach, W. AU - Fougere, C. PY - 2017 DA - 2017// TI - Impact of (18) F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis JO - Eur J Nucl Med Mol Imaging VL - 44 UR - https://doi.org/10.1007/s00259-017-3674-8 DO - 10.1007/s00259-017-3674-8 ID - Forschner2017 ER - TY - JOUR AU - Pflugfelder, A. AU - Kochs, C. AU - Blum, A. AU - Capellaro, M. AU - Czeschik, C. AU - Dettenborn, T. PY - 2013 DA - 2013// TI - Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma" JO - J Dtsch Dermatol Ges VL - 11 Suppl 6 UR - https://doi.org/10.1111/ddg.12113_suppl DO - 10.1111/ddg.12113_suppl ID - Pflugfelder2013 ER - TY - JOUR AU - Amin, M. B. AU - Greene, F. L. AU - Edge, S. B. AU - Compton, C. C. AU - Gershenwald, J. E. AU - Brookland, R. K. PY - 2017 DA - 2017// TI - The eighth edition AJCC Cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging JO - CA Cancer J Clin VL - 67 UR - https://doi.org/10.3322/caac.21388 DO - 10.3322/caac.21388 ID - Amin2017 ER - TY - JOUR AU - San-Millan, I. AU - Brooks, G. A. PY - 2017 DA - 2017// TI - Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg effect JO - Carcinogenesis. VL - 38 UR - https://doi.org/10.1093/carcin/bgw127 DO - 10.1093/carcin/bgw127 ID - San-Millan2017 ER - TY - JOUR AU - Hofmann, M. A. AU - Schicke, B. AU - Fritsch, A. AU - Biesold, S. AU - Gussmann, F. AU - Kuchler, I. PY - 2011 DA - 2011// TI - Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients JO - J Dermatol VL - 38 UR - https://doi.org/10.1111/j.1346-8138.2011.01219.x DO - 10.1111/j.1346-8138.2011.01219.x ID - Hofmann2011 ER - TY - JOUR AU - Kluger, H. M. AU - Hoyt, K. AU - Bacchiocchi, A. AU - Mayer, T. AU - Kirsch, J. AU - Kluger, Y. PY - 2011 DA - 2011// TI - Plasma markers for identifying patients with metastatic melanoma JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.Ccr-10-2402 DO - 10.1158/1078-0432.Ccr-10-2402 ID - Kluger2011 ER - TY - JOUR AU - Colombo, M. P. AU - Maccalli, C. AU - Mattei, S. AU - Melani, C. AU - Radrizzani, M. AU - Parmiani, G. PY - 1992 DA - 1992// TI - Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines JO - Melanoma Res VL - 2 UR - https://doi.org/10.1097/00008390-199209000-00006 DO - 10.1097/00008390-199209000-00006 ID - Colombo1992 ER - TY - JOUR AU - Kishimoto, T. PY - 1989 DA - 1989// TI - The biology of interleukin-6 JO - Blood. VL - 74 UR - https://doi.org/10.1182/blood.V74.1.1.1 DO - 10.1182/blood.V74.1.1.1 ID - Kishimoto1989 ER - TY - JOUR AU - Wolf, S. AU - Haase-Kohn, C. AU - Lenk, J. AU - Hoppmann, S. AU - Bergmann, R. AU - Steinbach, J. PY - 2011 DA - 2011// TI - Expression, purification and fluorine-18 radiolabeling of recombinant S100A4: a potential probe for molecular imaging of receptor for advanced glycation endproducts in vivo? JO - Amino Acids VL - 41 UR - https://doi.org/10.1007/s00726-010-0822-x DO - 10.1007/s00726-010-0822-x ID - Wolf2011 ER - TY - JOUR AU - Herwig, N. AU - Belter, B. AU - Wolf, S. AU - Haase-Kohn, C. AU - Pietzsch, J. PY - 2016 DA - 2016// TI - Interaction of extracellular S100A4 with RAGE prompts prometastatic activation of A375 melanoma cells JO - J Cell Mol Med VL - 20 UR - https://doi.org/10.1111/jcmm.12808 DO - 10.1111/jcmm.12808 ID - Herwig2016 ER - TY - JOUR AU - Peric, B. AU - Zagar, I. AU - Novakovic, S. AU - Zgajnar, J. AU - Hocevar, M. PY - 2011 DA - 2011// TI - Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma JO - BMC Cancer VL - 11 UR - https://doi.org/10.1186/1471-2407-11-328 DO - 10.1186/1471-2407-11-328 ID - Peric2011 ER - TY - JOUR AU - Harpio, R. AU - Einarsson, R. PY - 2004 DA - 2004// TI - S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma JO - Clin Biochem VL - 37 UR - https://doi.org/10.1016/j.clinbiochem.2004.05.012 DO - 10.1016/j.clinbiochem.2004.05.012 ID - Harpio2004 ER - TY - JOUR AU - Molina, R. AU - Navarro, J. AU - Filella, X. AU - Castel, T. AU - Ballesta, A. M. PY - 2002 DA - 2002// TI - S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function JO - Tumour Biol VL - 23 UR - https://doi.org/10.1159/000048687 DO - 10.1159/000048687 ID - Molina2002 ER - TY - JOUR AU - Tsoporis, J. N. AU - Mohammadzadeh, F. AU - Parker, T. G. PY - 2011 DA - 2011// TI - S100B: a multifunctional role in cardiovascular pathophysiology JO - Amino Acids VL - 41 UR - https://doi.org/10.1007/s00726-010-0527-1 DO - 10.1007/s00726-010-0527-1 ID - Tsoporis2011 ER - TY - JOUR AU - Warner, A. B. AU - Postow, M. A. PY - 2018 DA - 2018// TI - Combination controversies: checkpoint inhibition alone or in combination for the treatment of melanoma? JO - Oncology (Williston Park) VL - 32 ID - Warner2018 ER - TY - JOUR AU - Salavati, A. AU - Duan, F. AU - Snyder, B. S. AU - Wei, B. AU - Houshmand, S. AU - Khiewvan, B. PY - 2017 DA - 2017// TI - Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial JO - Eur J Nucl Med Mol Imaging VL - 44 UR - https://doi.org/10.1007/s00259-017-3753-x DO - 10.1007/s00259-017-3753-x ID - Salavati2017 ER - TY - JOUR AU - Schöder, H. AU - Moskowitz, C. PY - 2016 DA - 2016// TI - Metabolic tumor volume in lymphoma: hype or Hope? JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/jco.2016.69.3747 DO - 10.1200/jco.2016.69.3747 ID - Schöder2016 ER - TY - JOUR AU - Marinelli, B. AU - Espinet-Col, C. AU - Ulaner, G. A. AU - McArthur, H. L. AU - Gonen, M. AU - Jochelson, M. PY - 2016 DA - 2016// TI - Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients JO - Am J Nucl Med Mol Imaging VL - 6 ID - Marinelli2016 ER - TY - JOUR AU - Pak, K. AU - Cheon, G. J. AU - Nam, H. Y. AU - Kim, S. J. AU - Kang, K. W. AU - Chung, J. K. PY - 2014 DA - 2014// TI - Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis JO - J Nucl Med VL - 55 UR - https://doi.org/10.2967/jnumed.113.133801 DO - 10.2967/jnumed.113.133801 ID - Pak2014 ER - TY - JOUR AU - Kruijff, S. AU - Bastiaannet, E. AU - Speijers, M. J. AU - Kobold, A. C. M. AU - Brouwers, A. H. AU - Hoekstra, H. J. PY - 2011 DA - 2011// TI - The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection JO - Eur J Surg Oncol VL - 37 UR - https://doi.org/10.1016/j.ejso.2010.12.013 DO - 10.1016/j.ejso.2010.12.013 ID - Kruijff2011 ER - TY - JOUR AU - Bastiaannet, E. AU - Hoekstra, O. S. AU - Jong, J. R. AU - Brouwers, A. H. AU - Suurmeijer, A. J. H. AU - Hoekstra, H. J. PY - 2012 DA - 2012// TI - Prognostic value of the standardized uptake value for 18F-fluorodeoxyglucose in patients with stage IIIB melanoma JO - Eur J Nucl Med Mol Imaging VL - 39 UR - https://doi.org/10.1007/s00259-012-2182-0 DO - 10.1007/s00259-012-2182-0 ID - Bastiaannet2012 ER - TY - JOUR AU - Wagner, N. B. AU - Forschner, A. AU - Leiter, U. AU - Garbe, C. AU - Eigentler, T. K. PY - 2018 DA - 2018// TI - S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies JO - Br J Cancer VL - 119 UR - https://doi.org/10.1038/s41416-018-0167-x DO - 10.1038/s41416-018-0167-x ID - Wagner2018 ER - TY - JOUR AU - Bilski, J. AU - Mazur-Bialy, A. AU - Wojcik, D. AU - Zahradnik-Bilska, J. AU - Brzozowski, B. AU - Magierowski, M. PY - 2017 DA - 2017// TI - The role of intestinal alkaline phosphatase in inflammatory disorders of gastrointestinal tract JO - Mediat Inflamm VL - 2017 UR - https://doi.org/10.1155/2017/9074601 DO - 10.1155/2017/9074601 ID - Bilski2017 ER - TY - JOUR AU - Gabay, C. AU - Kushner, I. PY - 1999 DA - 1999// TI - Acute-phase proteins and other systemic responses to inflammation JO - N Engl J Med VL - 340 UR - https://doi.org/10.1056/nejm199902113400607 DO - 10.1056/nejm199902113400607 ID - Gabay1999 ER - TY - JOUR AU - Boellaard, R. AU - Delgado-Bolton, R. AU - Oyen, W. J. G. AU - Giammarile, F. AU - Tatsch, K. AU - Eschner, W. PY - 2015 DA - 2015// TI - FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 JO - Eur J Nucl Med Mol Imaging VL - 42 UR - https://doi.org/10.1007/s00259-014-2961-x DO - 10.1007/s00259-014-2961-x ID - Boellaard2015 ER -